Ferring Pharmaceutical officially opened its new 12,000-square-foot gene therapy manufacturing facility located within its US headquarters in Parsippany, New Jersey. The new facility produces Adstiladrin, the first and only FDA-approved gene therapy delivered directly to the bladder for high-risk, non-muscle-invasive bladder cancer (NMIBC).  According to reports, the company has invested more than $1 billion in developing ADSTILADRIN over 10 years. This included nearly $500 million in manu...